Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
151,6 EUR | -4,45% |
|
-5,22% | +8,94% |
03/07 | AbbVie verlaagt de winstverwachting voor 2024 | RE |
01/07 | Merus benoemt nieuwe Chief Medical Officer | MT |
Officiële publicaties
SEC Filing 10Q-1 | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
Proxy Statments | CO | |
SEC Filing 10K | CO | |
Annual results | CO | |
SEC Filing 8K | CO | |
SEC Filing 13G | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-3 | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-2 | CO | |
1st-half-year results | CO | |
SEC Filing 8K | CO | |
SEC Filing 4K | CO | |
SEC Filing 8K | CO | |
SEC Filing 4K | CO | |
Shareholders meeting voting results | CO | |
SEC Filing 10Q-1 | CO | |
SEC Filing 4K | CO | |
SEC Filing 4K | CO |
- Beurs
- Aandelen
- Koers ABBV
- Koers 4AB
- Nieuws AbbVie Inc.
- Officiële publicaties